ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO0993

Size Doesn't Matter? Effect of Donor Volume on Donor-Derived Cell-Free DNA in Kidney Transplant Recipients: A Single-Center Perspective

Session Information

Category: Transplantation

  • 2102 Transplantation: Clinical

Authors

  • Aloia, Sandra, Henry Ford Hospital, Detroit, Michigan, United States
  • Mahfouz, Ratib Talal, Henry Ford Hospital, Detroit, Michigan, United States
  • Sulejmani, Nimisha, Henry Ford Hospital, Detroit, Michigan, United States
  • Wright, Susan, Henry Ford Hospital, Detroit, Michigan, United States
  • Prashar, Rohini, Henry Ford Hospital, Detroit, Michigan, United States
  • Ansari, Rehan, Henry Ford Hospital, Detroit, Michigan, United States
Background

Donor-derived cell-free DNA (dd-cfDNA) has become an imperative noninvasive biomarker to identify subclinical allograft injury in kidney transplant recipients(KTRs). Multiple recipient factors including age, gender, pregnancy can influence dd-cfDNA levels. However the influence of donor factors are less known. We present our findings examining the impact of donor kidney volume on dd-cfDNA.

Methods

A retrospective chart review was conducted for living donor kidney KTRs who underwent transplantation between 1/2020 and 10/2023. KTRs who had volume (KV) and dd-cfDNA (AlloSure, CareDx) data available were included in the study. Descriptive statistics were used for 4 cohorts based on kidney volume (mL): cohort 1:90-130, cohort 2: 131-160; cohort 3: 161-190; cohort 4:191-230. One-way analysis of variance (ANOVA) was performed to assess statistical significance in dd-cfDNA and eGFR in recipients at baseline and at 1 year between cohorts.

Results

A total of 54 KTRs with KV and dd-cfDNA results met inclusion criteria. Median age at time of transplant for KTRs was 56.5 years with majority being white (66.7%) males (55.6%) with median BMI of 28.7. Median donor age was 41.5 years with BMI of 27.8. Majority donors were living related (61%) with 3 (5.5%) having hypertension. First dd-cfDNA was obtained at median of 34 days post-transplant with median being 0.18%. One-year dd-cfDNA was obtained at median of 355 days post-transplant with median being 0.18%. Similarly, eGFR at the time of 1st and 1-year dd-cfDNA was 50 and 58, respectively. When comparing dd-cfDNA and eGFR across 4 KV cohorts, there was no statistical significance noted.

Conclusion

This cohort of 54 living donor KTRs demonstrates that KV may not have a significant impact on dd-cfDNA in adult patients. Additionally, there was no impact on 1 year graft function.

Digital Object Identifier (DOI)